Page 1

Particulars AUROBINDO PHARMA LIMITED ( CIN L24239TG1986PLC015190 ) Regd . Office : Plot No.2 , Maitrivihar , Ameerpet , Hyderabad - 500 038 , India Tel : +91 040 23736370 ; Fax : +91 40 23747340 ; Email : info@aurobindo.com STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2021 30.06.2021 Unaudited Quarter ended 31.03.2021 Audited 30.06.2020 Unaudited ( Rs . In lakhs ) Year ended 31.03.2021 Audited 1 Revenue from operations ( a ) Net sales / Income from operations ( b ) Other operating income 288,564 811 410,361 1,042 334,354 Total revenue from operations 2 Other income 289,375 411,403 8,245 342,599 1,562,218 20,150 1,582,368 ( a ) Foreign exchange gain ( net ) ( refer note 7 ) 1,692 3,963 5,198 18,544 ( b ) Others 2,703 22,779 6,898 40,442 Total other income 4,395 26,742 12,096 58,986 Total Income ( 1 + 2 ) 293,770 438,145 354,695 1,641,354 3 Expenses ( a ) Cost of materials consumed 154,349 180,316 180,103 ( b ) Purchase of stock - In - trade 593 1,502 514 ( c ) Changes In Inventories of finished goods , stock - In - trade and work - in - progress ( 11,171 ) 12,733 ( 38,770 ) 721,573 2,609 299 ( d ) Employee benefits expense 43,077 44,473 42,732 ( e ) Finance costs 506 593 1,044 173,543 2,868 ( f ) Depreciation and amortisation expense 11,465 12,407 12,046 48,799 ( g ) Other expenses Total expenses 4 Profit before tax ( 1 + 2-3 ) 5 Tax expense Current tax Deferred tax Total tax expense 6 Profit for the period / year ( 4-5 ) 7 Other Comprehensive Income Items that will not to be reclassified subsequently to profit or loss : ( a ) Re - measurement of defined benefit liability ( b ) Income - tax relating to Items that will not be reclassified to profit or loss 8 Total Comprehensive Income for the perlod / year ( 6 + 7 ) 61,446 74,776 61,970 272,362 260,265 326,800 259,639 1,222,053 33,505 111,345 95,056 419,301 14,344 20,898 24,510 104,334 ( 2,346 ) 3,189 ( 207 ) 3,676 11,998 24,087 24,303 108,010 21,507 87,258 70,753 311,291 9 Paid - up equlty share capital ( face value Re . 1 per share ) 10 Other equity 11 Earnings per equity share ( face value Re . 1 per share ) ( a ) Basic ( in Rs . ) ( b ) Diluted ( in Rs . ) ( 246 ) 86 ( 254 ) 88 ( 482 ) 169 ( 986 ) 344 21,347 5,859 87,092 5,859 70,440 5,859 310,649 5,859 1,586,602 ( not annualised not annualised ( not annualised ) 3.67 ( Annualised ) 3.67 14.89 14.89 12.07 12.07 53.13 53.13 * PHARMA LTD 4 HYDERABAD Page 1 of 2